Galindo BM, Concepción D, Galindo MA, Pérez A, Saiz J

Language: Spanish
References: 40
Page: 1-7
PDF size: 2272.14 Kb.

ABSTRACT

Introduction: Cuba has implemented an effective National Immunization Program since 1962. The schedule, administered primarily to children, comprises 11 vaccines (8 domestically produced) protecting against 13 diseases. In 1999 Cuba launched a national vaccine adverse event surveillance system to monitor and assess the safety of the immunization program, its vaccination procedures and the products administered.
Objetive: Describe adverse events following vaccination reported in children aged ‹ 16 years in Cuba from 1999 through 2008.
Methods A retrospective descriptive study was conducted of adverse events following vaccination reported from January 1999 through December 2008. Variables used: year, number of adverse events, province, type of vaccine, type and severity of adverse events (common minor, rare, severe), vaccination program errors, number of deaths, and final results of investigations of severe events. Percentages and rates per dose administered were calculated. Adverse event rates were calculated per 100,000 doses administered and by percentages of individual effects among events reported.
Results: A total of 45,237,532 vaccine doses were administered, and 26,159 vaccine-associated adverse events were reported (overall rate: 57.8 per 100,000 doses). The group aged 0–5 years reported the highest rate of vaccine-associated adverse events (82/100,000 doses). The DTwP vaccine exhibited the highest rate of adverse events. Common minor events were: fever (17,538), reactions at injection site (4470) and systemic side effects (2422). Rare events (by WHO definition) reported were: persistent crying (2666), hypotonic-hyporesponsive episodes (3), encephalopathy (2) and febrile seizures (112). Severe events included: anaphylaxis (2), respiratory distress (1), multiple organ failure (1), sudden death (1), vaccine-associated paralytic poliomyelitis (2), toxic shock syndrome (3), and sepsis (1). The 10 deaths and 3 cases of disability were investigated by an expert commission, which concluded that 8 of the 13 severe events were vaccination-related.
Conclusions: Low rates of severe vaccine-associated adverse events observed in this study underline the low risk of vaccination relative to its demonstrated benefits in Cuba. Decision-making for the continued success of the National Immunization Program is supported by reliable information from comprehensive national surveillance with standarized reporting, along with multidisciplinary expert analysis of rare and severe adverse events and program errors.

REFERENCES

1. Vigilancia de los eventos supuestamente atribuidos a la vacunación o inmunización de la vacuna contra la gripe A (H1N1) y prevención de crisis. Washington DC: Pan American Health Organization; 2010. p. 4.

2. Vacunas e inmunización: Situación Mundial. 3rd ed. Geneva: World Health Organization; 2009. 16 p. Spanish.

3. Ochoa RF. Inmunoepidemiología y estrategias de vacunación. Havana: Ediciones Finlay; c2005. Chapter 3. p. 28. Spanish.

4. Wakefi eld AJ. MMR vaccination and autism. Lancet. 1999 Sep 11;354(9182):949–50.

5. Scanlon TJ. MMR vaccine uptake may by lower than reported because of manipulation of target groups. BMJ. 2002 Mar 23;324(7339):733.

6. Coombes R. Vaccine disputes. BMJ. 2009 Jun 22;338:b2435.

7. Chen RT. Vaccine risk: real perceived and unknown. Vaccine. 1999 Oct 29;17 Suppl 3:S41–6.

8. Olivera L, Castillo C, Donovano C, Peña J, Andrés J. Vacunación segura. Avances recientes en inmunización. In: Publicación Científi ca No. 619. 2nd ed. Washington: Pan American Health Organization; 2007. p. 69–86. Spanish.

9. Quadros CCA, Olivé JM, Cristina Nogueira C, Carrasco P, Silveira C. Programa Ampliado de Inmunización (PAI). In: Benguigui Y, Land S, Paganini JM, Yunes J, editors. Acciones de salud maternoinfantil a nivel local: según las metas de la Cumbre Mundial en favor de la infancia. Washington, D.C; Pan American Health Organization; 1999. p.141–72. Spanish.

10. Severini A, Battistini T, Pérez A, Lamy P, Fedelli S, Moreno J, et al. Estudio de un efecto adverso supuestamente atribuible a la vacunación e inmunización en el marco de una Campaña de Vacunación: experiencia en Catamarca. Rev Hosp Niños BAires. 2005 Oct;47(214):264–9. Spanish.

11. Pickering LK, Baker CJ, Freed L, Grogg S, Poland GA, Rodewal LE, et al. Infectious Diseases Society of America. Immunization Programs for Infants, Children, Adolescents, and Adults: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2009 Sep 15;49(6):817–40.

12. Vacunación segura. Módulos de capacitación. Módulo IV. Aspectos técnicos y clínicos de los eventos supuestamente atribuibles a la vacunación o inmunización (ESAVI). Washington DC: Pan American Health Organization; 2007. p. 2. Spanish.

13. Vacunación segura. ¿Cómo enfrentar los eventos supuestamente atribuidos a la vacunación e inmunización? Washington DC: Pan American Health Organization; 2002. p. 6. Spanish.

14. Vacunación segura. Módulos de capacitación. Módulo VI. Sistema de monitoreo de eventos supuestamente atribuidos a la vacunación. (ESAVI). Washington DC: Pan American Health Organization; 2007. p. 11–2.

15. Programa Nacional de Inmunización. Havana: Ministry of Public Health (CU); 1997. p. 2–3. Spanish.

16. Reed G, Galindo MA. Cuba’s National Immunization Program. MEDICC Rev. 2007 Oct;9(1):5–7.

17. Ministry of Public Health (CU); PAHO. Evaluación internacional del programa de inmunizaciones de Cuba. [International evaluation of Cuba’s immunization program] Final report. Havana: Ministry of Public Health (CU); 2004 Nov 29–Dec 11. 23 p. Spanish.

18. Programa de sistema de vigilancia de eventos adversos consecutivos a la vacunación. Havana: Ministry of Public Health (CU); 1999. Spanish.

19. Government Center for Drug Quality Control (CU). Regulación No. 17 – 2008. Directrices para la investigación de los eventos adversos supuestamente atribuibles a la vacunación o inmunización (ESAVI). Havana: Ministry of Public Health (CU); 2008. Spanish.

20. Vacunación segura ¿Cómo enfrentar los eventos supuestamente atribuidos a la vacunación e inmunización? Washington DC: Pan American Health Organization; 2002. p. 9–12. Spanish.

21. Galindo Santana BM, Galindo Sardiña MA, Pérez Rodríguez A. Sistema de vigilancia de eventos adversos consecutivos a la vacunación en la República de Cuba. Rev Cubana Med Trop. 1999 Sep–Dec;51(3):194–200. Spanish.

22. Ministry of Public Health National Medical Records and Health Statistics Bureau (CU). Anuario Estadístico de Salud 2009. Havana: Ministry of Public Health (CU); 2010 Apr. p. 112. Spanish.

23. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for Safety After Immunization: Vaccine Adverse Event Reporting System (VAERS) United States, 1991–2001. MMWR Surveill Summ. 2003 Jan 24;52(1):1–24.

24. Fernandes GC, Bastos Camacho LA, Sá Carvalho M. Surveillance system of vaccine adverse events and local data analysis – the experience in a middle-sized city in Brazil, 1999–2001. Vaccine. 2005 Mar 18;23(17– 18):2349–53.

25. Abarca VK, Cerda LJ, Ferreccio RC. Reacciones adversas a vacunas DPT del Programa Nacional de Inmunizaciones. Rev Med Chil. 2009 Jan;137(1):10–7. Spanish.

26. Carletti K, Dayan G, Katayfe F, Man C, Sanguinetti R, Tarlovsky A, et al. Reactogenicidad de la vacuna DPT acelular y celular. Arch Argent Pediatr. 1998 Apr;96(2):95–102. Spanish.

27. Kimura M, Kuno–Sakai H. Current epidemiology of pertussis in Japan. Pediatr Infect Dis J. 1990 Oct;9(10):705–9.

28. Cherry JD. The epidemiology of pertussis immunization in the United Kingdom and the United States: a comparative study. Curr Probl Pediatr. 1984 Feb;14(2):1–78.

29. Romanus V, Jonsell R, Bergguist SO. Pertussis in Sweden after the cessation of general immnunization in 1979. Pediatr Infect Dis J. 1987 Apr;6(4):364–71.

30. Zanoni G, Ferro A, Valsecchi M, Tridente G. The “Green Channel” of the Veneto region as a model for vaccine safety monitoring in Italy. Vaccine. 2005 Mar 18;23(17–18):2354–8.

31. Schonberger LB, McGowan JE, Gregg MB. Vaccine-associated poliomyelitis in the United States 1961–1972. Am J Epidemiol. 1976 Aug;104(2):202–11.

32. World Health Assembly. Global eradication of poliomyelitis by the year 2000. Resolution WHA 41.28. Geneva: World Health Organization; 1988.

33. Mas Lago P, Ferrer H, Goyenechea A, Galindo MA, Sarmiento L, Fonseca M. Casos de poliomielitis paralítica asociada a la vacuna oral antipoliomielítica en Cuba (1963–2006). Rev Cub Hig Epidemiol. 2008 May–Sep;46(2):1–14. Spanish.

34. Oliveira LH, Struchiner CJ. Vaccine-associated paralytic poliomyelitis in Brazil, 1989–1995. Rev Panam Salud Publica. 2000 Apr;7(4):219–24.

35. Kohl KS, Gidudu J, Bonhoeffer J, Braun MM, Buettcher M, Chen RT, et al. The development of standardized case defi nitions and guidelines for adverse events following immunization. Vaccine. 2007 Aug 1;25(31):5671–4.

36. Rüggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: Case defi nition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007 Aug 1;25(31):5675–84.

37. Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB, et al. Risk of Anaphylaxis After Vaccination of Children and Adolescents. Pediatrics. 2003 Oct;112(4):815–20.

38. Surveillance of adverse events following immunization. Field guide for Programme on Immunization [Internet]. Geneva: World Health Organization; 1997 [cited 2011 Feb 11]. Available from: http://www.who.int/vaccines-documents/ DocsPDF/www9541.pdf

39. Ball R, Halsey N, Braun MM, Moulton LH, Gale AD, Rammohan K, et al. Development of case defi nitions for acute encephalopathy, encephalitis and multiple sclerosis reports to the Vaccine Adverse Event Reporting System. J Clin Epidemiol. 2002 Aug;55(8):819–24.

40. OPS, OMS vacunación segura: Vigilancia de los ESAVIs de la vacunas contra la infl uenza pandémica A(H1N1) 2009 y prevención de crisis 2010; p. 11. Spanish.